Different types of botulinum toxin in humans

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Movement Disorders

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/mds.20010PMID 15027055
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure

  2003cited by this paper
• The normal appearing grey matter in primary progressive multiple sclerosis

  2003cited by this paper
• Quantitative sensory testing cannot differentiate simulated sensory loss from sensory neuropathy

  2003cited by this paper
• Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting.

  2002cited by this paper
• Clinical Features of Antibody-Induced Complete Secondary Failure of Botulinum Toxin Therapy

  2002cited by this paper
• Autonomic Side Effects of Botulinum Toxin Type B Treatment of Cervical Dystonia and Hyperhidrosis

  2002cited by this paper
• Spread of paralytic activity of neurobloc™ (botulinum toxin type B) and botox® (botulinum toxin type A) in juvenile monkeys: an electrophysiological model

  2001cited by this paper
• Pharmacology of botulinum toxin type B

  2001cited by this paper
• A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice.

  2001cited by this paper
• How botulinum and tetanus neurotoxins block neurotransmitter release.

  2000cited by this paper
• Neurotoxins affecting neuroexocytosis.

  2000cited by this paper
• Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.

  1999cited by this paper
• Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.

  1999cited by this paper
• Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.

  1999cited by this paper
• Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans.

  1998cited by this paper
• Mouse bioassay versus Western blot assay for botulinurn toxin antibodies Correlation with clinical response

  1998cited by this paper
• Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy

  1998cited by this paper
• Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections

  1998cited by this paper
• Botulinum toxin type F for treatment of dystonia

  1998cited by this paper
• Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia

  1997cited by this paper
• Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human.

  1997cited by this paper
• Human response to botulinum toxin injection: Type B compared with type A

  1997cited by this paper
• Peroxynitrite and Nitric Oxide Donors Induce Neuronal Apoptosis by Eliciting Autocrine Excitotoxicity

  1997cited by this paper
• Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology

  1997cited by this paper
• Botulinum toxin therapy, immunologic resistance, and problems with available materials

  1996cited by this paper
• Detection of the plasma cholinesterase K variant by PCR using an amplification-created restriction site.

  1996cited by this paper
• Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm : a double-blind, controlled study

  1996cited by this paper
• Response to botulinum toxin F in seronegative botulinum toxin A—resistant patients

  1996cited by this paper
• Therapy With Botulinum Toxin

  1995cited by this paper
• Tetanus and botulism neurotoxins: isolation and assay.

  1995cited by this paper
• Botulinum toxin type B in the treatment of cervical dystonia

  1995cited by this paper
• [39] Tetanus and botulism neurotoxins: Isolation and assay

  1995cited by this paper
• The mechanism of action of tetanus and botulinum neurotoxins.

  1995cited by this paper
• Structure and function of tetanus and botulinum neurotoxins

  1995cited by this paper
• Comparison of Therapeutic Efficacies of Type A and F Botulinum Toxins for Blepharospasm

  1995cited by this paper
• Response and immunoresistance to botulinum toxin injections

  1995cited by this paper
• Serial neurophysiological studies of intramuscular botulinum‐A toxin in humans

  1994cited by this paper
• Botulinum antibodies in dystonic patients treated with type A botulinum toxin

  1993cited by this paper
• Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A

  1993cited by this paper
• Therapeutic use of type F botulinum toxin.

  1992cited by this paper

• Immunogenicity of botulinum toxin products: the emergence of resistance and ways to overcome it

  2025cites this paper
• Regulation of Botulinum neurotoxin half‑life through the ubiquitin‑proteasome system.

  2025cites this paper
• Electrophysiological Evidence of Contralateral Neuromuscular Effects Following Long-Term Botulinum Toxin Therapy in Hemifacial Spasm

  2025cites this paper
• Botulinum toxin therapy for neurological disorders: Serendipitous benefits on sleep quality and underlying mechanisms.

  2025cites this paper
• Extraction and injection of botulinum toxin with less wastage

  2024cites this paper
• The analgesic effects of botulinum neurotoxin by modulating pain-related receptors; A literature review

  2024cites this paper
• Cellular and molecular mechanisms involved in the analgesic effects of botulinum neurotoxin: A literature review

  2024cites this paper
• Cosmetic Considerations in Dark-Skinned Patients

  2024cites this paper
• Model‐based interspecies interpretation of botulinum neurotoxin type A on muscle‐contraction inhibition

  2024cites this paper
• No Secondary Treatment Failure during Incobotulinumtoxin—A Long-Term Treatment Demonstrated by the Drawing of Disease Severity

  2023cites this paper
• A look at the future-new BoNTs and delivery systems in development: What it could mean in the clinic.

  2023cites this paper
• Characterization of Serotype CD Mosaic Botulinum Neurotoxin in Comparison with Serotype C and A

  2023cites this paper
• Clinical Onset of Action of Incobotulinum Toxin A Preparation.

  2022cites this paper
• Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update

  2022cites this paper
• The Multispecialty Toxin: A Literature Review of Botulinum Toxin

  2022cites this paper
• Botulinum Toxin: An Update on Pharmacology and Newer Products in Development

  2021cites this paper
• Posttranslational Regulation of Botulinum Neurotoxin Production in Clostridium botulinum Hall A-hyper

  2021cites this paper
• Clostridial Neurotoxins: Structure, Function and Implications to Other Bacterial Toxins

  2021cites this paper
• A Four-Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotypes C and D

  2021cites this paper
• Wound Botulism Caused by Botulinum Neurotoxin Type A in a Chronic Parenteral Drug Abuser

  2020cites this paper
• Tetanus Toxin cis-Loop Contributes to Light-Chain Translocation

  2020cites this paper
• Botulinum Neurotoxins: Mechanism of Action.

  2020cites this paper
• Clinical duration of action of different botulinum toxin types in humans.

  2020cites this paper
• Botulinum toxin

  2020cites this paper
• Botulinum Neurotoxins

  2020cites this paper
• Balancing Facial Muscle Forces in Surgical Procedures with Botulinum Toxin: A New Vision

  2020cites this paper
• Botulinum neurotoxins A, B, C, E, and F preferentially enter cultured human motor neurons compared to other cultured human neuronal populations

  2019cites this paper
• Safety and Pharmacokinetics of a Four Monoclonal Antibody Combination against Botulinum C and D Neurotoxins

  2019cites this paper
• Safety and pharmacodynamics of a novel recombinant botulinum toxin E (rBoNT-E): Results of a phase 1 study in healthy male subjects compared with abobotulinumtoxinA (Dysport®).

  2019cites this paper
• Interested in publishing with us ? Contact book

  2019cites this paper
• Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.

  2019cites this paper
• New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency

  2018cites this paper
• Urological Applications of Botulinum Toxin A

  2018cites this paper
• Botulinum neurotoxin formulations: overcoming the confusion

  2018cites this paper
• Effect of Hemifacial Spasm on Intraocular Pressure Measurement

  2018cites this paper
• Urological Applications of Botulinum Toxin A Urological Applications of Botulinum Toxin A

  2018cites this paper
• Nasal Reconstruction

  2018cites this paper
• Novel Botulinum Neurotoxins: Exploring Underneath the Iceberg Tip

  2018cites this paper
• Botulinum Toxins: Molecular Structures and Synaptic Physiology

  2018cites this paper
• Challenges in searching for therapeutics against Botulinum Neurotoxins

  2017cites this paper
• Effect of botulinum toxin A on vasoconstriction and sympathetic neurotransmitters in a murine random pattern skin flap model

  2017cites this paper
• Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology

  2017cites this paper
• Botulinum neurotoxin C mutants reveal different effects of syntaxin or SNAP-25 proteolysis on neuromuscular transmission

  2017cites this paper
• The Evidence Base for Botulinum Toxin Injection for the Treatment of Cerebral Palsy–Related Spasticity in the Lower Limb: The Long-Term Effects

  2017cites this paper
• Substrate cleavage and duration of action of botulinum neurotoxin type FA (“H, HA”)

  2017cites this paper
• The first non Clostridial botulinum-like toxin cleaves VAMP within the juxtamembrane domain

  2016cites this paper
• Stationäre und mobile Verfahren zur Detektion und Differenzierung biologischer Toxine

  2016cites this paper
• The role of botulinum toxin A in treating neurogenic bladder

  2016cites this paper
• Tetanus and Botulinum Neurotoxins

  2016cites this paper
• Donor Site Aesthetic Enhancement With Preoperative Botulinum Toxin in Forehead Flap Nasal Reconstruction

  2016cites this paper
• Botulinum Toxin for the Treatment of Refractory Erythema and Flushing of Rosacea

  2016cites this paper
• Botulinum Toxin for the Treatment of Refractory Erythema and Flushing of Rosacea

  2015cites this paper
• Pathogenesis of Clostridium botulinum in Humans

  2015cites this paper
• Clinical differences between botulinum neurotoxin type A and B.

  2015cites this paper
• On Botulinum Neurotoxin Variability

  2015cites this paper
• Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism.

  2015cites this paper
• Chapter 28 – Botulinum Toxin*

  2015cites this paper
• Current Status and Future Directions of Botulinum Neurotoxins for Targeting Pain Processing

  2015cites this paper
• Incobotulinumtoxina (Xeomin®) Versus Onabotulinumtoxina (Botox®): Evaluation of Clinical Onset of Action with Rating Scales and Electroneurography

  2015cites this paper
• Molecular Mechanism and Effects of Clostridial Neurotoxins

  2014cites this paper
• Botulinum Toxin as a Clinical Product: Manufacture and Pharmacology

  2014cites this paper
• Comparison and overview of currently available neurotoxins.

  2014cites this paper
• Long‐term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm

  2014cites this paper
• Clinical Applications of Botulinum Neurotoxin

  2014cites this paper
• Advanced Botulinum Toxin Injections for Dynamic Rhytides: Treating the Upper Face, Lower Face, and Beyond

  2014cites this paper
• The Botulinum Neurotoxin Complex and the Role of Ancillary Proteins

  2014cites this paper
• Botulinum toxin type A in the healing of chronic lesion following bilateral spasticity of gluteus muscle

  2014cites this paper
• Unizentrische Kohortenstudie zum integrativen Therapiekonzept bei Kindern mit bilateral spastischer Cerebralparese unter besonderer Berücksichtigung der Adhärenz zu der Behandlung mit Botulinumtoxin

  2013cites this paper
• Facial Blanching Due to Neurotoxins: Proposed Mechanisms

  2013cites this paper
• The effects of botulinum toxin injection frequency on calf muscle growth in young children with spastic cerebral palsy: a 12-month prospective study

  2013cites this paper
• Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study.

  2013cites this paper
• Diffusion, spread, and migration of botulinum toxin

  2013cites this paper
• Therapeutic effectiveness of botulinum neurotoxin A: potent blockade of autonomic transmission by targeted cleavage of only the pertinent SNAP-25.

  2013cites this paper
• The thioredoxin reductase‐thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals

  2013cites this paper
• Progress in cell based assays for botulinum neurotoxin detection.

  2013cites this paper
• The entry of tetanus and botulinum neurotoxins into neurons

  2013cites this paper
• Botulinum toxin type A: implications in wound healing, facial cutaneous scarring, and cleft lip repair

  2013cites this paper
• Botulinum toxins in the treatment of dystonia

  2012cites this paper
• Efficacy and Safety of Long-term Botulinum Toxin Treatment in Craniocervical Dystonia: A Systematic Review

  2012cites this paper
• Learning from the past: historical aspects of bacterial toxins as pharmaceuticals.

  2012cites this paper
• Diffusion of Botulinum Toxins

  2012cites this paper
• 6 Botulinum Neurotoxins

  2012cites this paper
• Treating benign prostatic hyperplasia with botulinum neurotoxin.

  2011cites this paper
• An update on the mechanism of action of tetanus and botulinum neurotoxins.

  2011cites this paper
• Efficacy of Shock Wave Therapy on Spasticity and Hand Function in Children with Cerebral Palsy

  2011cites this paper
• Targeted secretion inhibitors-innovative protein therapeutics.

  2010cites this paper
• Targeted Secretion Inhibitors—Innovative Protein Therapeutics

  2010cites this paper
• Quantification of potency of neutralizing antibodies to botulinum toxin using compound muscle action potential (CMAP).

  2010cites this paper
• Temporal characteristics of botulinum neurotoxin therapy

  2010cites this paper
• Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins.

  2010cites this paper
• Botulinum Toxin

  2010cites this paper
• The effect of botulinum toxin A on skin flap survival in rats

  2009cites this paper
• Current clinical applications of botulinum toxin.

  2009cites this paper
• Chapter 6 – Biology and Clinical Pharmacology of Botulinum Neurotoxin Type C and Other Non-A/Non-B Botulinum Neurotoxins

  2009cites this paper
• Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg

  2009cites this paper
• Chapter 11 Botulism

  2008cites this paper
• Botulinum Toxin: Non-cosmetic Indications and Possible Mechanisms of Action

  2008cites this paper
• Studies, reports say botulinum toxins may have effects beyond injection site.

  2008cites this paper
• Botulinum Toxin for Pain

  2008cites this paper
• Presynaptic neurotoxins with enzymatic activities.

  2008cites this paper